As January unfolds, the disclosure of the 2024 annual reports by A-share listed companies has commenced. To date, 257 pharmaceutical enterprises have unveiled their report cards, with over 40% anticipating favorable results. In terms of net profit, 16 companies have exceeded the 10 billion yuan mark, with Xinhecheng breaking through the 50 billion yuan threshold for the first time, and Pien Tze Huang, Huahai Pharmaceutical, and Sinopharm Modern reaching new highs. Regarding growth rates, more than 50 companies, including Zhejiang Medicine, Darentang, Huiyu Pharmaceutical, and Sansheng Guojian, have seen their profits double, with North China Pharmaceutical leading the pack at a staggering 2456.08% increase. Additionally, 25 companies such as Hisun Pharmaceutical, Aosaikang, and ST Bailing have turned losses into gains. However, over 100 companies reported losses, an increase compared to the same period last year, with 30 or more companies experiencing increased losses, reduced losses, or reporting losses for the first time.